Belzutifan
Belzutifan is indicated for the treatment of von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC), which is a type of kidney cancer that occurs in people with VHL disease. VHL disease is a rare genetic disorder that can cause the development of tumors in various parts of the body, including the kidneys. Belzutifan works by inhibiting a protein called hypoxia-inducible factor (HIF), which is involved in the growth and spread of these tumors. By blocking HIF, belzutifan can help slow or stop the growth of tumors in people with VHL disease-associated RCC.